• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pulmonary Fibrosis - Pipeline Review, H2 2012 Product Image

Pulmonary Fibrosis - Pipeline Review, H2 2012

  • Published: November 2012
  • 175 pages
  • Global Markets Direct

Pulmonary Fibrosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pulmonary Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pulmonary Fibrosis.
- A review of the Pulmonary Fibrosis products under development by companies and universities/research READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Pulmonary Fibrosis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pulmonary Fibrosis 9
Pulmonary Fibrosis Therapeutics under Development by Companies 11
Pulmonary Fibrosis Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Pulmonary Fibrosis Therapeutics – Products under Development by Companies 21
Pulmonary Fibrosis Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Pulmonary Fibrosis Therapeutics Development 25
Bristol-Myers Squibb Company 25
Genzyme Corporation 26
Johnson & Johnson 27
Boehringer Ingelheim GmbH 28
Sanofi-Aventis 29
MedImmune LLC 30
Gilead Sciences, Inc. 31
FibroGen, Inc. 32
Novartis AG 33
Actelion Ltd 34
InterMune, Inc. 35
Celgene Corporation 36
Geron Corporation 37
IntelGenx Technologies Corp. 38
Lpath, Inc. 39
Oncothyreon Inc 40
Compugen Ltd. 41
Pharmaxis Ltd. 42
Hanall Pharmaceutical Co., Ltd. 43
LTT Bio-Pharma Co., Ltd. 44
Paloma Pharmaceuticals, Inc. 45
Digna Biotech, S.L. 46
Auspex Pharmaceuticals 47
Aquinox Pharmaceuticals Inc. 48
Promedior, Inc. 49
Mondobiotech Holding AG 50
Fresenius Biotech GmbH 51
GenKyoTex S.A. 52
Angion Biomedica Corp. 53
Stromedix, Inc. 54
ImmuneRegen BioSciences, Inc. 55
Centocor Ortho Biotech, Inc. 56
ImmuneWorks, LLC 57
Pacific Therapeutics Ltd. 58
Pulmonary Fibrosis – Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 66
fresolimumab - Drug Profile 66
tralokinumab - Drug Profile 67
tanzisertib - Drug Profile 68
pirfenidone - Drug Profile 69
Lpathomab - Drug Profile 71
FG-3019 - Drug Profile 72
macitentan - Drug Profile 74
Homspera - Drug Profile 76
P-17 Systemic - Drug Profile 78
PC-SOD - Drug Profile 79
CGEN-25009 - Drug Profile 81
AZX-100 - Drug Profile 82
PX-866 - Drug Profile 84
PXS-25 - Drug Profile 85
PXS-64 - Drug Profile 86
MMI-0100 - Drug Profile 87
nintedanib - Drug Profile 88
PRM-151 - Drug Profile 90
AP-2966 - Drug Profile 92
STX-100 - Drug Profile 93
QAX-576 - Drug Profile 94
IW-001 - Drug Profile 96
Prednisone + Azathioprine + N-Acetylcysteine - Drug Profile 98
GKT-137831 - Drug Profile 99
carlumab - Drug Profile 100
pentoxifylline + n-acetylcysteine - Drug Profile 102
ATG-Fresenius S - Drug Profile 103
GRN-510 - Drug Profile 105
Aerosol Interferon Gamma - Drug Profile 106
Viagra + Cozaar - Drug Profile 107
Losartan + Zileuton + N-Acetylcysteine + Prevastatin + Erythromycin - Drug Profile 108
pirfenidone - Drug Profile 109
bosentan - Drug Profile 110
GS-6624 - Drug Profile 111
BMS-986202 - Drug Profile 113
Cyclophosphamide + Prednisone - Drug Profile 114
carbon monoxide - Drug Profile 115
Palomid 529 Inhalant - Drug Profile 116
AQX-1125 - Drug Profile 117
Btx-201 - Drug Profile 118
AB-0023 - Drug Profile 119
AM-095 - Drug Profile 120
hPTX-2 - Drug Profile 121
Plasma Exchange + Rituximab + Corticosteroids - Drug Profile 122
SAR-156597 - Drug Profile 123
Drug For Immunology - Drug Profile 124
pirfenidone - Drug Profile 125
ICG-001 - Drug Profile 126
aviptadil - Drug Profile 127
interferon gamma-1b - Drug Profile 128
DasKloster 0228-01 - Drug Profile 129
ANG-3298 - Drug Profile 130
HL-156Fib - Drug Profile 131
INT-0024 - Drug Profile 132
C-201 - Drug Profile 133
C-301 - Drug Profile 134
nitric oxide - Drug Profile 135
Pulmonary Fibrosis Therapeutics – Drug Profile Updates 137
Pulmonary Fibrosis Therapeutics – Discontinued Products 159
Pulmonary Fibrosis Therapeutics - Dormant Products 160
Pulmonary Fibrosis – Product Development Milestones 161
Featured News & Press Releases 161
Appendix 170
Methodology 170
Coverage 170
Secondary Research 170
Primary Research 170
Expert Panel Validation 170
Contact Us 171
Disclaimer 171

List of Tables
Number of Products Under Development for Pulmonary Fibrosis, H2 2012 13
Products under Development for Pulmonary Fibrosis – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Bristol-Myers Squibb Company, H2 2012 29
Genzyme Corporation, H2 2012 30
Johnson & Johnson, H2 2012 31
Boehringer Ingelheim GmbH, H2 2012 32
Sanofi-Aventis, H2 2012 33
MedImmune LLC, H2 2012 34
Gilead Sciences, Inc., H2 2012 35
FibroGen, Inc., H2 2012 36
Novartis AG, H2 2012 37
Actelion Ltd, H2 2012 38
InterMune, Inc., H2 2012 39
Celgene Corporation, H2 2012 40
Geron Corporation, H2 2012 41
IntelGenx Technologies Corp., H2 2012 42
Lpath, Inc., H2 2012 43
Oncothyreon Inc, H2 2012 44
Compugen Ltd., H2 2012 45
Pharmaxis Ltd., H2 2012 46
Hanall Pharmaceutical Co., Ltd., H2 2012 47
LTT Bio-Pharma Co., Ltd., H2 2012 48
Paloma Pharmaceuticals, Inc., H2 2012 49
Digna Biotech, S.L., H2 2012 50
Auspex Pharmaceuticals, H2 2012 51
Aquinox Pharmaceuticals Inc., H2 2012 52
Promedior, Inc., H2 2012 53
Mondobiotech Holding AG, H2 2012 54
Fresenius Biotech GmbH, H2 2012 55
GenKyoTex S.A., H2 2012 56
Angion Biomedica Corp., H2 2012 57
Stromedix, Inc., H2 2012 58
ImmuneRegen BioSciences, Inc., H2 2012 59
Centocor Ortho Biotech, Inc., H2 2012 60
ImmuneWorks, LLC, H2 2012 61
Pacific Therapeutics Ltd., H2 2012 62
Assessment by Monotherapy Products, H2 2012 63
Assessment by Combination Products, H2 2012 64
Assessment by Stage and Route of Administration, H2 2012 66
Assessment by Stage and Molecule Type, H2 2012 69
Pulmonary Fibrosis Therapeutics – Drug Profile Updates 141
Pulmonary Fibrosis Therapeutics – Discontinued Products 163
Pulmonary Fibrosis Therapeutics – Dormant Products 164

List of Figures
Number of Products under Development for Pulmonary Fibrosis, H2 2012 13
Products under Development for Pulmonary Fibrosis – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 63
Assessment by Combination Products, H2 2012 64
Assessment by Route of Administration, H2 2012 65
Assessment by Stage and Route of Administration, H2 2012 66
Assessment by Molecule Type, H2 2012 67
Assessment by Stage and Molecule Type, H2 2012 68

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos